Farhad Fakhrejahani

Recombinant Human Factor VIIa for Alveolar Hemorrhage Following Allogeneic Stem Cell Transplantation

Jason M. Elinoff, Brad Moriyama, Jennifer L. Dreiling et al. · Biology of Blood and Marrow Transplantation · 2014 · 41 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Avelumab in metastatic castration-resistant prostate cancer (mCRPC).

Farhad Fakhrejahani, Ravi A. Madan, William L. Dahut et al. · Journal of Clinical Oncology · 2017 · 34 citations

Medicine, Oncology, Pharmacology +17

Symptoms of ovarian cancer in young patients 2 years before diagnosis, a case-control study

Nadereh Behtash, E Ghayouri Azar, Farhad Fakhrejahani · European Journal of Cancer Care · 2008 · 25 citations

Medicine, Gynecology, Oncology +13

Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).

Fatima Karzai, Ravi A. Madan, Helen Owens et al. · Journal of Clinical Oncology · 2017 · 22 citations

Medicine, Oncology, Pharmacology +17

A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC).

Fatima Karzai, Ravi A. Madan, Helen Owens et al. · Journal of Clinical Oncology · 2017 · 20 citations

Medicine, Oncology, Pharmacology +17